In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: Complexation with hydroxypropyl-β-cyclodextrin in the presence of HPMC

被引:34
作者
Kou, Wen [1 ]
Cai, Cuifang [1 ]
Xu, Shuying [1 ]
Wang, Huan [1 ]
Liu, Jing [1 ]
Yang, Dan [1 ]
Zhang, Tianhong [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning Prov, Peoples R China
关键词
Carbamazepine; HP-beta-CD; HPMC; Bioavailability; Dissolution; UPLC/MS/MS; PHARMACEUTICAL APPLICATIONS; MATRIX TABLETS; BIOAVAILABILITY; SOLUBILITY; PHARMACOKINETICS; FORMULATION; INCLUSION; DOGS;
D O I
10.1016/j.ijpharm.2011.02.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Carbamazepine (CBZ)-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) complex in the presence of HPMC was prepared and characterized by differential scanning calorimetry (DSC) and X-ray diffractometer intended for improving the dissolution rate of CBZ. The phase-solubility method was used to investigate the effect of HP-beta-CD and HPMC on the solubility of CBZ. Tablets of the resulting complex were prepared using direct compression method and the bioavailability was evaluated in beagle dogs using a UPLC/MS/MS method. The results showed solubility of CBZ was increased up to 95 times by complexation with HP-beta-CD in the presence of 0.1% HPMC. The results of DSC and X-ray diffraction proved a formation of complex between CBZ and HP-beta-CD. Dissolution rate of CBZ was notably improved from complex tablets with more than 97.39% released within 10 min; whereas for the commercial tablets, around 60% was released within 30 min. Using commercial tablets as the reference formulation, the bioavailability of complex tablets was considerably increased by 1.5-fold (P < 0.05) and T-max was reduced to 0.88 h compared with 1.25 h for commercial tablets. Furthermore, a lower inter-subject variability (49.9%) was observed compared with that of the commercial tablets (39.7%). It is evident from the results herein that complexation with HP-beta-CD in the presence of HPMC is a feasible way to prepare a rapidly acting and better absorbed CBZ oral product. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 26 条
[1]   Formulation, Release Characteristics and Bioavailability Study of Oral Monolithic Matrix Tablets Containing Carbamazepine [J].
Barakat, Nahla S. ;
Elbagory, Ibrahim M. ;
Almurshedi, Alanood S. .
AAPS PHARMSCITECH, 2008, 9 (03) :931-938
[2]   CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :128-143
[3]   ORAL PHARMACOKINETICS OF CARBAMAZEPINE IN DOGS FROM COMMERCIAL TABLETS AND A CYCLODEXTRIN COMPLEX [J].
BETLACH, CJ ;
GONZALEZ, MA ;
MCKIERNAN, BC ;
NEFFDAVIS, C ;
BODOR, N .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (10) :1058-1060
[4]   DEVELOPMENT OF AQUEOUS PARENTERAL FORMULATIONS FOR CARBAMAZEPINE THROUGH THE USE OF MODIFIED CYCLODEXTRINS [J].
BREWSTER, ME ;
ANDERSON, WR ;
ESTES, KS ;
BODOR, N .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (04) :380-383
[5]   Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions [J].
Brewster, ME ;
Anderson, WR ;
Meinsma, D ;
Moreno, D ;
Webb, AI ;
Pablo, L ;
Estes, KS ;
Derendorf, H ;
Bodor, N ;
Sawchuk, R ;
Cheung, B ;
Pop, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :335-339
[6]  
Chinese Pharmacopoeia, 2010, PHARM PEOPL REP CHIN, V2, P126
[7]   IMPROVEMENT OF ORAL BIOAVAILABILITY OF CARBAMAZEPINE BY INCLUSION IN 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN [J].
CHOUDHURY, S ;
NELSON, KF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 85 (1-3) :175-180
[8]  
Cirri M, 2009, DRUG DEV IND PHARM, V35, P73, DOI [10.1080/03639040802192798, 10.1080/03639040802192798 ]
[9]  
El-Gindy GA, 2002, STP PHARMA SCI, V12, P369
[10]   Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation [J].
El-Zein, H ;
Riad, L ;
El-Bary, AA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 168 (02) :209-220